How Long To Study For Ccsk
Dinah Lianes
Cloud is currently used throughout the globe by businesses across all industries. The Certificate of Cloud Security Knowledge (CCSK) shows that you have a broad understanding of the security considerations when using cloud-based technologies (regardless of the specific cloud provider or vendor). As a bonus, the CCSK course contains sample questions and pointers to reference material for additional studying.
PrerequisitesThe CCSK exam itself does not require any formal experience or pre-requisites. The course materials assume you have a basis in IT technologies, but does not require in-depth technical knowledge of the cloud.
- Understand topics covered in the CCSK exam
- Demonstrate competence in cloud security topics
- Identify additional resources to prepare for the CCSK exam and to leverage * in your professional career when working with the cloud
As more companies migrate to the cloud, they need IT professionals who understand the importance of cloud security. The CCSK certification provides students with the foundations necessary to secure data in the cloud and prepares them for the CCSK certification exam.
- have the technical abilities, skills, and expertise to develop cloud security environments by maintaining accepted standards
- stand out from noncertified professionals for employment and advancement in the ever-growing cloud job market
- gain access to career resources, like networking, tools, and exchange of ideas with other professionals
The topics that are covered on the CCSK exam include cloud architecture, security compliance, operations, encryption, governance, virtualization, and more. The exam is comprised of 60 multiple choice questions, for which test-takers have 90 minutes to complete. To pass, a score of 80% must be achieved.
Is Earning the CCSK Certification Worth It?With the current demand for IT professionals of all types, any technology certification can be said to be worth it. The CCSK certification specifically, is worth earning for a number of valid reasons, including:
What's the Best way to Prepare for the CCSK Certification Exam?Being properly prepared for the CCSK certification exam is vital. One of the most effective ways to prepare for this certification exam is by taking a CCSK training course that cover all the applicable information and provides students with the opportunity to apply their knowledge in a hands-on environment.
At Cybrary, we provide students with the CCSK course that will help them to become prepared for the certification exam. Students who take the training will learn skills and information that are needed to pass the test and earn their CCSK credential. Enrolling for the course is simple, just click on the Register button in the top right corner of the screen.
I am a client-focused IT strategist with 20 years of experience leading change in development and operations programs to solve complex technology and cultural problems that have a positive impact on businesses. Accomplishing organizational success by fostering people, leveraging cross functional partnerships, adopting appropriate agile practices, and contributing architectural competencies in cutting edge software platforms. I have a deep understanding of working in a highly regulated environment, in particular healthcare, to meet compliance obligations while minimizing cost overhead.
In recent years, I have focused a lot in the technology areas of cybersecurity (secure application development), cloud, and device-to-cloud (IoT) solutions, with a sprinkling of data science and analytics (to measure and monitor success indicators).
Cybrary provides me with an outlet to share what I know about technology and learn from others that have a different perspective (stemming from working at different companies, working in different industries, having a different educational background, etc.). As a lifelong learner myself, I appreciate the opportunity to work with a range of students to discuss the variety of ways to apply technology and process to improve the services they provide and products they create.
Several histologic variants of CCSK are recognized. The most common variant is the myxoid CCSK. This histology features diffuse accumulation of mucopolysaccharide matrix material between tumor cells sometimes creating a cystic appearance. The sclerosing variant of CCSK is characterized by prominent collagen bundles that may isolate single or small groups of tumor cells in a dense matrix that may become hyalinized. The cellular pattern of CCSK is characterized by less extracellular matrix material between cells with overlapping of nuclei, a feature that may lead to confusion with a blastemal predominant Wilms tumor or primitive neuroectodermal tumor. Mitotic activity is usually increased in this variant. The epithelioid CCSK variant may be confused with nephroblastoma due to condensation of tumor cell cords. The palisading pattern is described as having spindle cell nuclei in parallel linear arrays alternating with nuclear free zones, a feature that resembles Verocay bodies of schwannomas. The spindle cell and storiform patterns are relatively uncommon. Anaplasia is a rare finding in CCSK (3% of cases), and is characterized by the presence of enlarged, hyperchromatic polypoid nuclei with multipolar mitotic figures. The nuclear accumulation of p53 in anaplastic tumors is thought to represent evidence of p53 gene mutation, a finding that has been well-documented in anaplastic Wilms tumors. The frequency of different CCSK variants is listed below:
- Myxoid pattern (50%)
- Sclerosing pattern (35%)
- Cellular pattern (26%)
- Epithelioid pattern (trabecular or acinar type) (13%)
- Palisading (verocay-body) pattern (11%)
- Spindle cell pattern (7%)
- Storiform pattern (4%)
- Anaplastic pattern (2.6%) Immunohistochemistry is rarely informative in CCSK. Immunoreactivity for the intermediate filament vimentin is usually present, however, reactivity with most other proteins including epithelial markers are negative. Like other renal tumors of childhood, CCSK is staged by the National Wilms Tumor Study staging scheme as follows: Stage I (25% of CCSK): For stage I tumors, 1 or more of the following criteria must be met:
- Tumor is limited to the kidney and is completely excised.
- The surface of the renal capsule is intact.
- The tumor is not ruptured or biopsied (open or needle) prior to removal.
- No involvement of renal sinus vessels.
- No residual tumor apparent beyond the margins of excision. Stage II (37% of CCSK): For Stage II tumors, 1 or more of the following criteria must be met:
- Tumor extends beyond the kidney but is completely excised.
- No residual tumor apparent at or beyond the margins of excision.
Any of the following conditions may also exist: - Tumor involvement of the blood vessels of the renal sinus and/or outside the renal parenchyma.
- The tumor has been biopsied prior to removal or there is local spillage of tumor during surgery, confined to the flank. Stage III (34% of CCSK): For Stage III tumors, 1 or more of the following criteria must be met:
- Unresectable primary tumor.
- Lymph node metastasis.
- Positive surgical margins.
- Tumor spillage involving peritoneal surfaces either before or during surgery, or transected tumor thrombus. Stage IV (4% of CCSK): defined as the presence of hematogenous metastases (lung, liver, bone, or brain), or lymph node metastases outside the abdomenopelvic region. Stage V (not yet reported for CCSK): defined as bilateral renal involvement at time of initial diagnosis.(A) Hemisection of kidney demonstrating large tan-yellow mass characteristic of CCSK.
(B) Histologic section of CCSK characterized by hyperchromatic cells with high nuclear-cyto-plasmic ratios and abundant extracellular matrix material.(C) p53 immunochemistry with only rare cells showing nuclear accumulation of protein.TreatmentTreatment of CCSK generally involves surgical intervention coupled with radiation and chemotherapy. CCSK commonly responds poorly to treatment with vincristine and actinomycin alone, but the addition of doxorubicin to chemotherapy regimens has improved survival rates. In the NWTS-5 protocol, patients with all stages of CCSK are treated with the same regimen used in patients who have Wilms tumor with diffuse anaplasia with the exception of stage I tumors. This treatment protocol is comprised of radical nephrectomy followed by radiotherapy and chemotherapy with cyclophosphamide, etoposide, vincristine, and doxorubicin for 24 weeks.PrognosisThe prognosis for CCSK, particularly for low stage tumors, has improved with the addition of doxorubicin to chemotherapy regimens with a 66% reduction in overall mortality. Stage-dependent six-year survival is 97% for stage I tumors, 75% for stage II tumors, 77% for stage III tumors, and 50% for stage IV tumors.
Patients with tumors without areas of necrosis have a more favorable prognosis. Twenty-nine percent of patients with CCSK have lymph node metastases at the time of diagnosis, and bone metastasis is the most common form of relapse. Metastatic lesions have also been reported in the liver, brain, soft tissue sites, and lung with more unusual metastases to the skeletal muscle, testis, and salivary gland. Relapses of CCSK as many as 10 years after original diagnosis have been reported.CytogeneticsNoteOnly a small number of CCSK cases have been described cytogenetically. A clonal reciprocal 10;17 translocation t(10;17)(q22;p13) in CCSK was first reported in 1989. A CCSK with a complex karyotype including trisomy 9, deletions of chromosomes 16 and 22, and loss of chromosome 1p13 has been reported. In the same case, an interstitial deletion of chromosome 14 was reported: del(14)(q23). One of two sarcomatous Wilms tumors also contained a t(10;17)(q11;p12) as a part of an abnormal karyotype. Three of four other patients with CCSK were normal whereas one patient harbored a t(2;22)(q21;q11). Comparative genomic hybridization analysis of CCSK has documented quantitative chromosomal abnormalities in only 4 of 30 CCSK cases. These four cases included a gain of chromosome 1q and loss of 10q, gain of 1q and loss of terminal 4p, gain of 19p, and loss of chromosome 19. Later, another CCSK with a t(10;17)(q22;p13) was reported. Of five patients reviewed at this institution, karyotypes were available for four of these. One patient had a clonal balanced translocation 10;17 and an interstitial deletion of the long arm of chromosome 14 as follows: 46, XY, t(10;17)(q22;p13)del(14)(q24.1q31.1).Three other patients had normal karyotypes. Fluorescent in-situ hybridization using a p53 probe was employed on the same cells harboring the clonal translocation above. This study documented the presence of two p53 signals on chromosome 17 indicating the absence of deletion or translocation of the TP53 tumor suppressor gene.t(10;17)(q22;p13)Genes Involved and ProteinsNoteNo gene has been implicated in the pathogenesis of CCSK. However, given the recurrent finding of clonal balanced translocations involving t(10;17)(q22;p13), gene(s) located within these regions may be related to CCSK pathogenesis. The chromosome 17p13 locus harbors the TP53 tumor suppressor gene, but several studies have failed to implicate mutations of p53 in CCSK. Tumor suppressor and oncogenes present on chromosome 10q22 include LCX and TET1. Both of these genes are involved in fusion gene products in acute myeloid leukemias. Tumor suppressor and/or oncogenes located in the deleted region of chromosome 14q24.1q31.1 include CHES1, a member of the forkhead family of transcription factors involved in cell cycle checkpoint control, hREC2, a gene encoding a protein with amino acid homology to a RAD51 involved in DNA double strand break repair, MAP3K9 or mitogen activated protein kinase, the MAX transcription factor, placental growth factor (VEGF-related protein), and transforming growth factor beta-3.BibliographyPubmed IDLast YearTitleAuthors106324832000Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center.Argani P et al106578722000Comparative genomic hybridization analysis of clear cell sarcoma of the kidney.Barnard M et al120070182002Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma.Brownlee NA et al89123501996Implications of p53 protein expression in clear cell sarcoma of the kidney.Cheah PL et al29816071985Abnormalities of chromosomes 1 and 11 in Wilms' tumor.Douglass EC et al120657732002Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.Hsueh C et al16573741991Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.Kaneko Y et al7085761978Bone-metastasizing renal tumour of childhood.Marsden HB et al2131871978Undifferentiated sarcoma of the kidney: a tumor of childhood with histopathologic and clinical characteristics distinct from Wilms' tumor.Morgan E et al84535491993Clear cell sarcoma of kidney. Two cases in adults.Oda H et al25487051989Translocation 10;17 in clear cell sarcoma of the kidney. A first report.Punnett HH et al154741572004Translocation (10;17)(q22;p13): a recurring translocation in clear cell sarcoma of kidney.Rakheja D et al21583981990Chromosome analysis of 31 Wilms' tumors.Sheng WW et alExternal Links- OMIM database
- Cosmic database
- Genecards database
- Mitelman database